NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aimmune Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.05 -0.21 (-0.80 %) (As of 02/24/2020 04:00 PM ET) Add Compare Today's Range$24.01Now: $26.05▼$26.5250-Day Range$26.26MA: $31.48▼$36.5452-Week Range$16.95Now: $26.05▼$37.00Volume1.85 million shsAverage Volume1.81 million shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/ABeta0.04 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webhttp://www.aimmune.com/ Phone650-614-5220Debt Debt-to-Equity Ratio0.33 Current Ratio4.64 Quick Ratio4.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.09 per share Price / Book5.12Profitability EPS (Most Recent Fiscal Year)($3.67) Net Income$-210,750,000.00 Net MarginsN/A Return on Equity-104.54% Return on Assets-77.54%Miscellaneous Employees228 Outstanding Shares62,669,000Market Cap$1.63 billion Next Earnings Date2/27/2020 (Confirmed) OptionableOptionable Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AIMT Rates by TradingView Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) EPS for the quarter, meeting the consensus estimate of ($1.03). During the same period last year, the company posted ($0.89) EPS. View Aimmune Therapeutics' Earnings History. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics. How can I listen to Aimmune Therapeutics' earnings call? Aimmune Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What price target have analysts set for AIMT? 11 equities research analysts have issued twelve-month price objectives for Aimmune Therapeutics' stock. Their forecasts range from $27.00 to $81.00. On average, they expect Aimmune Therapeutics' share price to reach $48.82 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics. What is the consensus analysts' recommendation for Aimmune Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (2/5/2020) 2. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019) Has Aimmune Therapeutics been receiving favorable news coverage? News stories about AIMT stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aimmune Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aimmune Therapeutics. Are investors shorting Aimmune Therapeutics? Aimmune Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 11,570,000 shares, an increase of 6.4% from the January 15th total of 10,870,000 shares. Based on an average trading volume of 888,400 shares, the short-interest ratio is currently 13.0 days. Approximately 29.0% of the company's shares are sold short. View Aimmune Therapeutics' Current Options Chain. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE) and Zai Lab (ZLAB). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), CA (CA), Amarin (AMRN), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK) and Roku (ROKU). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the folowing people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (5.39%), FMR LLC (4.59%), State Street Corp (3.51%), Victory Capital Management Inc. (3.44%), Victory Capital Management Inc. (3.41%) and Alliancebernstein L.P. (3.30%). Company insiders that own Aimmune Therapeutics stock include Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman and Stephen George Dilly. View Institutional Ownership Trends for Aimmune Therapeutics. Which major investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, Palo Alto Investors LP, UBS Group AG, Alliancebernstein L.P., State of New Jersey Common Pension Fund D, Citigroup Inc. and Rice Hall James & Associates LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman and Douglas T Sheehy. View Insider Buying and Selling for Aimmune Therapeutics. Which major investors are buying Aimmune Therapeutics stock? AIMT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, FMR LLC, Fiera Capital Corp, New York State Common Retirement Fund, Bank of America Corp DE and Geode Capital Management LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Eric Bjerkholt, Jayson Donald Alexander Dallas and Kathryn E Falberg. View Insider Buying and Selling for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $26.05. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.63 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is http://www.aimmune.com/. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 440 (Vote Outperform)Underperform Votes: 298 (Vote Underperform)Total Votes: 738MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?
